BIONDVAX PHARMA/S (BVXV) Lifted to Strong-Buy at ValuEngine

BIONDVAX PHARMA/S (NASDAQ:BVXV) was upgraded by stock analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday, April 9th, ValuEngine reports.

NASDAQ:BVXV remained flat at $$7.05 during trading hours on Tuesday. The company’s stock had a trading volume of 1,307 shares, compared to its average volume of 6,966. The company has a current ratio of 20.74, a quick ratio of 20.74 and a debt-to-equity ratio of 2.95. The stock has a market cap of $46.07 million, a PE ratio of -3.56 and a beta of 1.33. BIONDVAX PHARMA/S has a 12 month low of $3.51 and a 12 month high of $7.26.

BIONDVAX PHARMA/S (NASDAQ:BVXV) last issued its earnings results on Tuesday, April 30th. The company reported ($1.81) earnings per share (EPS) for the quarter. Analysts predict that BIONDVAX PHARMA/S will post -0.05 EPS for the current year.

About BIONDVAX PHARMA/S

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.

Read More: Understanding Stock Ratings

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.